ES2172474B1 - Derivados de glutarimida como agentes terapeuticos. - Google Patents

Derivados de glutarimida como agentes terapeuticos.

Info

Publication number
ES2172474B1
ES2172474B1 ES200100488A ES200100488A ES2172474B1 ES 2172474 B1 ES2172474 B1 ES 2172474B1 ES 200100488 A ES200100488 A ES 200100488A ES 200100488 A ES200100488 A ES 200100488A ES 2172474 B1 ES2172474 B1 ES 2172474B1
Authority
ES
Spain
Prior art keywords
derivatives
imide
therapeutic agents
glutarimide derivatives
glutarimide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200100488A
Other languages
English (en)
Other versions
ES2172474A1 (es
Inventor
Brana Miguel Fernandez
Diaz Loereto Anorbe
Martin Gema Dominguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion Universitaria San Pablo CEU
Original Assignee
Fundacion Universitaria San Pablo CEU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Universitaria San Pablo CEU filed Critical Fundacion Universitaria San Pablo CEU
Priority to ES200100488A priority Critical patent/ES2172474B1/es
Priority to PCT/ES2002/000092 priority patent/WO2002070480A1/es
Publication of ES2172474A1 publication Critical patent/ES2172474A1/es
Application granted granted Critical
Publication of ES2172474B1 publication Critical patent/ES2172474B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nuevos derivados de glutarimida de fórmula general I, así como sus homólogos de naturaleza dimérica I-Q-I, donde Z puede ser una imida o una bisimida de diversos tipos, e Y y Q pueden ser diferentes tipos de átomos, cadenas o grupos de química orgánica, caracterizados dichos derivados por su actividad antiangiogénica concominante de los tumores sólidos y por su acción inhibidora del factor de necrosis tumoral alfa (TNF-). Estos compuestos son preparados mediante los métodos generales de síntesis de imidas, obteniéndose las diferentes sales, profármacos de sales y medicamentos para su utilización en la terapia coadyuvante anticancerosa, por cualquier medio disponible en clínica.
ES200100488A 2001-03-01 2001-03-01 Derivados de glutarimida como agentes terapeuticos. Expired - Fee Related ES2172474B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES200100488A ES2172474B1 (es) 2001-03-01 2001-03-01 Derivados de glutarimida como agentes terapeuticos.
PCT/ES2002/000092 WO2002070480A1 (es) 2001-03-01 2002-03-01 Derivados de glutarimida como agentes terapeuticos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100488A ES2172474B1 (es) 2001-03-01 2001-03-01 Derivados de glutarimida como agentes terapeuticos.

Publications (2)

Publication Number Publication Date
ES2172474A1 ES2172474A1 (es) 2002-09-16
ES2172474B1 true ES2172474B1 (es) 2004-01-16

Family

ID=8496938

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200100488A Expired - Fee Related ES2172474B1 (es) 2001-03-01 2001-03-01 Derivados de glutarimida como agentes terapeuticos.

Country Status (2)

Country Link
ES (1) ES2172474B1 (es)
WO (1) WO2002070480A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518281B2 (en) 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
CN100383139C (zh) * 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
DK2683708T3 (da) 2011-03-11 2018-01-29 Celgene Corp Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
JP7143296B2 (ja) * 2016-11-24 2022-09-28 ティアンジン ヘメイ ファーマスーティカル サイ－テック カンパニー リミテッド ピペリジン－２，６－ジオン誘導体及び潰瘍性結腸炎の治療
WO2018191219A1 (en) * 2017-04-11 2018-10-18 Thottathil John K Novel alpha-hydroxy carboxylic acid and derivatives and other gras- based amide and imide prodrugs of amphetamine compounds and uses thereof
AU2019381688A1 (en) 2018-11-13 2021-06-03 Biotheryx, Inc. Substituted isoindolinones

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL25595A (en) * 1965-05-08 1971-01-28 Gruenenthal Chemie New history of cyclic amide compounds and process for the production of these compounds
US3553217A (en) * 1968-10-18 1971-01-05 Aldrich Chem Co Inc 2-(quinolinimido)glutarimide
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
WO1998044908A1 (en) * 1997-04-07 1998-10-15 The Board Of Trustees Of The Leland Stanford Junior University Method of regulating epithelial growth

Also Published As

Publication number Publication date
ES2172474A1 (es) 2002-09-16
WO2002070480A1 (es) 2002-09-12

Similar Documents

Publication Publication Date Title
HN2002000067A (es) Inhibidores de la rho - quinasa.
CY1113538T1 (el) Παραγωγα της 5-αμινο-2,4,7-τριοξο-3,4,7,8-τετραϋδρο-2η-πυριδο[2,3-d] πυριμιδινης και παρομοιες ενωσεις για την αγωγη του καρκινου
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
ECSP066447A (es) Derivados de isoquinolina 1,4-disustituida como inhibidores raf-quinasa útiles para el tratamiento de enfermedades proliferativas
PA8501801A1 (es) Inhibidores triciclicos de polimerasas (adp - polirribosas)
CY1108129T1 (el) Παραγωγα 4-αμινο-6-φαινυλ-πυρρολο[2,3-δ]πυριμιδινης
DE60318177D1 (de) Rho-kinase inhibitoren
UY27225A1 (es) Inhibidores de la rho-quinasa
PA8571001A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
CY1113924T1 (el) Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων
CY1111692T1 (el) ΠΑΡΑΓΩΓΑ ΙΝΔΟΛΗΣ Ή ΒΕΝΖΙΜΙΔΑΖΟΛΗΣ ΓΙΑ ΤΗ ΡΥΘΜΙΣΗ ΤΗΣ ΙκΒ ΚΙΝΑΣΗΣ
CY1111203T1 (el) 4-ανιλινοκινολινο-3-καρβοξαμιδια ως αναστολεις κινασης csf-1r
DE50310516D1 (de) Fredericamycin-derivate
CL2004000720A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLIDINA-1,2-DICARBOXILDIFENILAMIDA, INHIBIDORES DE LOS FACTORES DE COAGULACION Xa, VIIa; PROCESO DE PREPARACION; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; KIT FARMACEUTICO; Y SU USO PARA TRATAR TROMBOSIS, INFAR
CY1109728T1 (el) Νεα παραγωγα υδαντοϊνης για τη θεραπεια αποφρακτικων νοσηματων της αναπνευστικης οδου
BRPI0409198A (pt) derivados quinolin-2-ona para o tratamento de doenças de vias aéreas
CY1111538T1 (el) Φωσφοραμιδικα παραγωγα νουκλεοζιτικων ενωσεων για χρηση στην αντιμετωπιση καρκινου
ECSP034809A (es) Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc
CY1107080T1 (el) Υποκατεστημενες ινδολο-βασεις του mannich
CY1106801T1 (el) Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
ECSP10010361A (es) Derivados de piridazinona
CR7510A (es) DERIVADOS DE [1-4] DIAZEPINO[6,7,1-iJ)] QUINOLONA COMO AGENTES ANTIPSICOTICOS Y CONTRA LA OBESIDAD
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
CY1106526T1 (el) Παραγωγα ν-θειαζολ-2-υλο-βενζαμιδης

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020916

Kind code of ref document: A1

Effective date: 20020916

FG2A Definitive protection

Ref document number: 2172474B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20210625